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Activation of phospholipase A 2 (PLA 2 ) liberates arachidonic acid (AA) from phospholipids. AA metabolites, including prostaglandins, leukotrienes, lipoxins, and hydroxy derivatives, have been implicated in numerous physiological and pathophysiological processes (1) (2) (3) (4) (5) . Recent studies using ''knock-out'' mice or inhibitors indicate that AA-generating cytosolic PLA 2 (cPLA 2 ) plays a role in macrophage production of inflammatory mediators, reproductive physiology, allergic responses, postischemic brain injury, cell proliferation, and cancer (6) (7) (8) (9) . Neurotransmitters, hormones, and growth factors activate cPLA 2 and protein kinases in many cell types, including vascular smooth muscle cells (VSMCs) (10) (11) (12) (13) (14) . The adrenergic transmitter norepinephrine (NE) and angiotensin II (Ang II), by promoting extracellular Ca 2ϩ influx, increases Ca 2ϩ ͞calmodulin-dependent kinase II (CaMKII) activity, leading to activation of mitogen-activated protein kinase (MAPK) and cPLA 2 , resulting in release of AA for prostacyclin synthesis (15, 16) . This pathway of MAPK activation by CaMKII is mediated through stimulation of MAPK kinase (MEK). CaMKIV expressed in PC-12 cells has also been shown to activate MAPKs (17) . MAPKs are also stimulated by ␤␥ subunits of heterotrimeric G proteins (18, 19) . However, the mechanism by which CaMK activates MAPK is not known.
AA is metabolized by cyclooxygenase into prostaglandins and thromboxane A 2 , by lipoxygenase into leukotrienes and hydroxyeicosatetraenoic acids (HETEs) [5-, 12 (S)-, and 15-HETE], and by cytochrome P450 (CYP450) into epoxyeicosatrienoic acid and 12(R),19-and 20-HETE (1, 3) . AA and some of its lipoxygenase products (12-and 15-HETE) stimulate MAPK activity (20) (21) (22) . Moreover, 5-HETE has been shown to increase cPLA 2 activity in human neutrophils (23) . These observations led us to hypothesize that the NE-induced increase in MAPK activity is caused by AA or its metabolites generated through activation of cPLA 2 by CaMKII. To test this hypothesis, we investigated the effects of NE, Ang II, and epidermal growth factor (EGF) on Ras, MAPK, CaMKII, and cPLA 2 activity in the presence and absence of inhibitors of CYP450, lipoxygenase, and cyclooxygenase in rabbit aortic VSMCs. We have found that NE, Ang II, and EGF activate the Ras͞MAPK pathway through generation of a CYP450 metabolite of AA, 20-HETE, after initial activation of cPLA 2 by CaMKII. Activation of MAPK by 20-HETE amplifies cPLA 2 activity and releases additional AA by a positive feedback mechanism.
MATERIALS AND METHODS
Preparation of VSMCs. Aortae were rapidly removed from male New Zealand White rabbits and the VSMCs were isolated as described (24) . Cells between passages 2 and 8 were plated in 12-or 24-well plates or 100-mm plates. Cells were maintained under 5% CO 2 in M-199 medium (Sigma) with penicillin, streptomycin, and 10% fetal bovine serum.
Experimental Protocol. VSMCs that were arrested for 48 h with medium containing 0.05% fetal bovine serum were used for all studies. Cells were incubated with inhibitors of cPLA 2 (methylarachidonylfluorophosphonate, MAFP) (25) ; MEK (PD-98059) (26) ; CaMKII (KN-93) (27) ; cyclooxygenase (indomethacin) (28) ; lipoxygenase (baicalein, BACL) (29); CYP450 (17-octadecynoic acid, 17-ODYA) (30) ; farnesyltransferase (FPT III) (31); or their respective vehicles and exposed to NE (10 M); AA (1-20 M); Ang II (100 nM); EGF (100 nM); 5-, 12(R)-, 12(S)-, 15-, or 20-HETEs (1-250 nM); or their vehicles for an additional 5-15 min. The concentrations of various inhibitors used in our study have been reported to be effective in blocking the activity of these enzymes in other cell systems (25) (26) (27) (28) (29) (30) (31) . MAFP and HETEs were obtained from Cayman Chemicals (Ann Arbor, MI). NE, myelin basic protein, and indomethacin were from Sigma. Ang II was from Bachem. AA was from Nu Chek Prep (Elysian, MN). PD-98059 was from New England Biolabs. Indomethacin, 17-ODYA, and BACL were from Biomol (Plymouth Meeting, PA). FPT III and KN-93 were from Calbiochem.
Enzyme Assays. In vitro MAPK assays: The activity of MAPK was determined in VSMC lysates with a Biotrak kit (Amersham) using a peptide substrate KRELVEPLTPAGEAPNQALLR as directed by the manufacturer's instructions.
In-Gel MAPK Assay. MAPK activity was measured in VSMC homogenates by renaturation assay in polyacrylamide gels containing myelin basic protein as described (32) .
In The aqueous medium was collected, and AA metabolites were extracted and separated with a binary gradient HPLC system (Waters Associates) using a Nucleosil C 18 column (5 M) with a two-solvent gradient elution as described (34) . The column eluate was monitored at 235 nm, and radioactivity in the samples was measured by liquid scintillation spectrometry.
Western Blotting of CYP450 4A. Lysate and microsomal proteins of VSMCs were separated on an SDS͞polyacrylamide gel (10%), transferred to a nitrocellulose membrane, and incubated Approximately 100-200 g of proteins from microsomes and lysates were subjected to SDS͞PAGE (10% gel) and detected by Western blotting using a rat CYP450 4A polyclonal antibody raised in goats. Lanes (from left to right) are clofibrate-treated liver microsomes as a standard, VSMC lysates (two lanes), and microsomes isolated from rabbit VSMCs.
for 16 h with rat CYP450 4A antibody (Gentest, Woburn, MA; 1:500 dilution) raised in goats. The immunoblots were developed by using an enhanced chemiluminescence kit (Amersham).
Raf Phosphorylation. Raf-1 kinase threonine phosphorylation was determined in cell lysates. The cell lysates were immunoprecipitated with anti-phosphothreonine antibody (Sigma). The immunoprecipitates were separated in a 7.5% SDS͞polyacrylamide gel and transferred to nitrocellulose membrane; Raf-1 kinase was detected by the enhanced chemiluminescence method with antiRaf-1 kinase antibody (Upstate Biotechnology, Lake Placid, NY).
Translocation of Ras. Cells were fixed in 4% paraformaldehyde in buffer (10 mM Pipes͞5 mM EGTA͞2 mM MgCl 2 ͞0.2% Triton) for 3 min and postfixed in 95% ethanol for 5 min at Ϫ20°C. Cells were visualized with anti-Ras (Santa Cruz Biotechnology) and Texas red-conjugated horse anti-mouse IgG (Vector Laboratories) by confocal microscopy (Bio-Rad, MRC-1000, Laser Scanning Confocal Imaging system using an argon͞krypton lamp) as described (15 2 , MAPK, and CaMKII activity and AA release were variable in different batches of cells, the effect of agonists and inhibitors on the activity of these enzymes and AA release was consistent within each batch of cells. Therefore, the changes produced by agonists and inhibitors have been presented as percent above basal. The results are expressed as mean Ϯ SEM. Data were analyzed with one-way ANOVA. The Newman-Keuls multiple range test was applied to determine the difference among multiple groups, and an unpaired Student's t test was used to determine the difference between two groups. Differences were considered significant at P Ͻ 0.05.
RESULTS

CYP450 and Lipoxygenase Metabolites of Arachidonic Acid
Mediate NE-Induced MAPK Activity in Rabbit VSMCs. MAFP, an inhibitor of cPLA 2 (25) , attenuated the NE-induced increase in cPLA 2 and MAPK activity but not in CaMKII activity ( Fig. 1  A and B) . This raises the possibility that the NE-induced increase in MAPK activity is caused by AA or its metabolites generated through activation of cPLA 2 by CaMKII. That an inhibitor of AA metabolism, 5,8,11,14-eicosatetraynoic acid (35) , decreased MAPK but not CaMKII activity (data not shown) supports this hypothesis.
If AA metabolites activate MAPK in VSMCs, then inhibition of the AA-metabolizing enzymes CYP450, lipoxygenase, and͞or cyclooxygenase should attenuate the NE-induced increase in MAPK and cPLA 2 activities. The inhibitors of CYP450 (17-ODYA) and, to a lesser degree, lipoxygenase (BACL) attenuated the NE-induced increase in MAPK and cPLA 2 activity but not CaMKII activity (Fig. 1C-F) . Indomethacin did not affect NEinduced activation of MAPK or cPLA 2 activity. Exogenous AA increased MAPK and cPLA 2 activity, and this effect was also inhibited by 17-ODYA and by BACL. AA also increased CaMKII activity, but this was not inhibited by 17-ODYA or BACL (data not shown). The inhibitors of CYP450 (17-ODYA), lipoxygenase (BACL), and MEK (PD-98059) (Fig. 1G) , which diminished the activities of extracellular regulated kinase (ERK) 1 and ERK2 (Fig. 1D and ref. 15) , did not completely block the NE-and AA-induced increases in cPLA 2 activity.
Metabolism of AA by CYP450 and Lipoxygenase in Rabbit VSMCs. In VSMCs, AA is metabolized by cyclooxygenase to prostaglandins and thromboxane A 2 and by lipoxygenase to 5-, 12(S)-, or 15-HETE (36) . Since the NE-induced increase in MAPK activity was not only attenuated by a lipoxygenase inhibitor but also by a CYP450 inhibitor, we investigated the production of CYP450 metabolites of AA in rabbit VSMCs. We found by reverse-phase HPLC that AA is metabolized by CYP450 to hydroxy acid(s), one of which has been tentatively identified as 20-HETE (Fig. 2) . The calculated amount of this product was approximately 0.5 g͞mg of protein. Further studies are needed to confirm the identity of this peak. Moreover, we demonstrated that CYP4A protein, which may be involved in the formation of 20-HETE (37) , is expressed in these cells (Fig. 2) . (Fig. 3) . 20-HETE also caused activation of MAPK, measured as ERK1 and ERK2, in the presence of inhibitors of CYP450 and lipoxygenase (Fig. 3D ). 20-HETE increased MAPK activity at concentrations as low as 0.1 M; the maximal effect was produced at 1 M. The effect of 12(S)-, 15-, and 20-HETE of stimulating MAPK and cPLA 2 was attenuated by the MEK inhibitor PD-98059 (Fig. 3A) , suggesting that these effects could be mediated by MEK or other signaling elements upstream of MEK. 20-HETE Mediates NE-Induced Activation of Ras͞Raf Pathways in Rabbit VSMCs. Many agonists stimulate MEK activity by promoting phosphorylation of proximal kinases, including c-Raf; Raf is known to be activated by Ras and recruited to the plasma membrane (38) . In the present study, NE and 20-HETE increased Raf phosphorylation in VSMCs and increased the translocation of Ras to the plasma membrane. 17-ODYA and BACL blocked this effect of NE but not of 20-HETE (Fig. 4) . Farnesylation of Ras by farnesyltransferase is required for proper membrane localization and activity of Ras (39, 40) . FPT III, which inhibits farnesyltransferase activity (31) , also blocked the NE-and 20-HETE-induced translocation of Ras to the plasma membrane (Fig. 4B) . Moreover, FPT III attenuated MAPK and cPLA 2 activities and the AA release elicited by NE (Fig. 4C) . Thus, 20-HETE may activate Raf in VSMCs by promoting the translocation of Ras to the plasma membrane.
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20-HETE Mediates Ang II-and EGF-Induced Ras͞MAPK Activation.
Ang II and EGF may also stimulate MAPK through CYP450 and lipoxygenase products of AA released by initial activation of cPLA 2 by CaMKII. Ang II-and EGF-induced activation of MAPK was attenuated by inhibitors of CYP450 and lipoxygenase (Fig. 5A) . Moreover, Ang II and EGF caused translocation of Ras to the plasma membrane, and this was inhibited by a combination of 17-ODYA and BACL and by FPT III (Fig. 5B) . FPT III also attenuated MAPK activity and AA release elicited by Ang II and EGF (Fig. 5C ). The inhibitory effect of 17-ODYA and BACL on the Ang II-and EGF-induced increase in MAPK activity and Ras translocation was reversed by 20-HETE (data not shown).
DISCUSSION
NE, through ␣ 1 -and ␣ 2 -adrenergic receptors, stimulates influx of extracellular Ca 2ϩ (41) and activates CaMKII in rabbit VSMCs (15) . The CaMKII in turn stimulates MAPK and increases cPLA 2 activity, resulting in the release of AA for prostaglandin synthesis (15) . The present study demonstrates a mechanism by which a CYP450 metabolite of AA, 20-HETE, mediates NE-, Ang II-, and EGF-stimulated CaMKII-induced activation of the Ras͞ MAPK pathway. MAPK then amplifies cPLA 2 activity and releases further AA for prostaglandin synthesis.
In the present study, the cPLA 2 inhibitor MAFP and the inhibitor of AA metabolism 5,8,11,14-eicosatetraynoic acid attenuated NE-induced MAPK activity. These results suggest that a metabolite of AA and not this fatty acid itself is involved in CaMKII-induced MAPK activation. An important finding is that inhibitors of CYP450 (17-ODYA) and lipoxygenase (BACL), but not of cyclooxygenase (indomethacin), attenuated the NE-and AA-induced increase in MAPK and cPLA 2 and not the CaMKII activities in VSMCs. From these observations, it follows that products of AA generated by CYP450 and lipoxygenase but not by cyclooxygenase contribute to the activation of MAPK and cPLA 2 elicited by NE. Although the combination of 17-ODYA, BACL, and the MEK inhibitor PD-98059 abolished the NEinduced increase in MAPK activity, measured as ERK1 and ERK2, it only partially reduced cPLA 2 activity. We have reported that CaMKII mediates activation of cPLA 2 and MAPK in response to NE (15) . Therefore, it appears that NE-stimulated CaMKII activates cPLA 2 and releases AA and that products of AA generated via CYP450 and lipoxygenase stimulate MAPK, which then amplifies cPLA 2 activity and releases additional AA. Although CaMKII activates cPLA 2 in VSMCs, it inhibits PLA 2 activity in rat brain synaptosomes (42) . This could be due to differences in the species of PLA 2 activity in intact synaptosomes but does not alter PLA 2 activity in rabbit VSMCs (41) .
In VSMCs, AA is metabolized by lipoxygenase into 5-, 12-, and 15-HETE (36) . The present study indicates that rabbit VSMCs also express CYP450 4A enzyme, which may be involved in the formation of 20-HETE. 12(S)-, 15-, and 20-HETE increased MAPK and cPLA 2 activities and AA release in rabbit VSMCs. However, 20-HETE (a CYP450 product) was more potent than 12(S)-or 15-HETE (lipoxygenase products) in stimulating MAPK and cPLA 2 activity. Moreover, the CYP450 inhibitor (17-ODYA) produced a much greater reduction than the lipoxygenase inhibitor (BACL) in NE-induced MAPK and cPLA 2 activities. These results raise the possibility that a product(s) of AA generated via CYP450, most likely 20-HETE, plays a major role in regulating NE-induced activation of MAPK and, consequently, amplification of cPLA 2 activity.
Our studies also indicate that MEK mediates NE-and 12(S)-, 15-, and 20-HETE-induced MAPK activation because the MEK inhibitor PD-98059 attenuated these agents' effect of increasing MAPK activity. Since PD-98059 selectively inhibits MEK1 (26) , it appears that MAPK stimulation is mediated primarily by MEK1. However, we cannot exclude the participation of other MEK family members that stimulate MAPKs, including c-jun N-terminal kinase and p38 MAPK.
It is well established that Raf activates MEK (43) . Our demonstration that the NE-increased phosphorylation of c-Raf was inhibited by ODYA and BACL is consistent with a role for Raf in activation of MEK by NE. Also supporting this view is the finding that 20-HETE increased Raf phosphorylation in VSMCs.
NE stimulates Ras in human VSMCs (44) , and Ras stimulates Raf by promoting its association with the plasma membrane (45) . The finding that translocation of Ras by NE was blocked by inhibitors of CYP450 and lipoxygenase suggests that metabolites of AA activate Raf in VSMCs by promoting the translocation of Ras to the plasma membrane. The findings that 20-HETE translocated Ras to the plasma membrane and that the farnesyltransferase inhibitor FPT III blocked the Ras translocation elicited by NE and by 20-HETE supports this contention.
The positive feedback mechanism of Ras͞MAPK activation by CYP450 and lipoxygenase products of AA may be a general mechanism in the actions of hormones like Ang II and growth factors such as EGF. Ang II and EGF are known to stimulate AA release, MAPK activity, and cell growth (12, 16, 46, 47) . EGF increased CaMKII activity and AA release in rabbit VSMCs; this effect was inhibited by removal of calcium from the medium or addition of the CaMKII inhibitor KN-93 (data not shown). In the present study, both Ang II and EGF increased MAPK activity and the translocation of Ras to the plasma membrane, and these effects were inhibited by 17-ODYA and BACL and by the farnesyltransferase inhibitor FPT III. It would appear that these agents, like NE, generate AA metabolites through initial activation of cPLA 2 by CaMKII, which stimulates Ras and activates MAPK, amplifies cPLA 2 activity, and releases additional AA for prostanoid synthesis. In rat VSMCs, Ang II-induced MAPK activation has been reported to be Ras-independent (47, 48) . However, another study conducted in the same cell system proposed that Ang II-induced MAPK activation was Ras-dependent and is mediated by an unidentified Ca 2ϩ ͞CaM-dependent tyrosine kinase through transactivation of the EGF receptor (14, 49) .
The mechanism by which 20-HETE activates Ras is unknown and is currently being investigated. HETEs may activate Ras by hydroxy arachidonylation of Ras, which could promote its binding to the plasma membrane and subsequent activation. The modification of ␣ subunits of G proteins by myristoylation, arachidonylation, and͞or palmitoylation (50) and of Ras by farnesylation (39, 40 ) is known to be required for anchorage to membrane or interaction with other proteins. In human platelets, ␣ subunits of G proteins (␣ i , ␣ q , ␣ z, and ␣ 13 ) have been shown to covalently bind arachidonate and palmitate but not myristate (50) . The present study proposes a signaling mechanism by which NE, Ang II, and EGF activate the Ras͞MAPK pathway through generation of an AA metabolite of CYP450, 20-HETE (Fig. 6) . The activation of MAPK by 20-HETE amplifies cPLA 2 activity and releases additional AA by a positive feedback mechanism (Fig. 6 ). This mechanism of Ras͞MAPK activation by 20-HETE might play a central role in other signaling processes involved in inflammation and in cell growth, proliferation, and differentiation.
